Roche to Acquire Piramed for $160 Million, Adventrx Pharma Appoints Jose Hechavarria VP of Manufacturing, More
Piramed, a privately owned biotechnology company, signed a definitive agreement with Roche (Basel) that will result in Piramed being fully acquired for an upfront cash payment of $160 million plus a milestone payment of $15 million, which is due upon the commencement of Phase II clinical trials for the company's oncology program. Closing of the transaction is subject to standard conditions and reviews. Read More
Comments